Comparative cost-benefit analyses of paricalcitol and calcitriol in stage 4 chronic kidney disease from the perspective of a health plan

Clinical Drug Investigation

Volumn 27, Issue 2, 2007, Pages 105-113

  Gal Moscovici, Anca ^a,b   Sprague, Stuart M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; PARICALCITOL;

ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; COST OF ILLNESS; DIABETES MELLITUS; DRUG COST; HEALTH CARE; HEALTH CARE PLANNING; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; HYPERTENSION; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM;

CALCITRIOL; CALCIUM CHANNEL AGONISTS; COST-BENEFIT ANALYSIS; ERGOCALCIFEROLS; HOSPITALIZATION; HUMANS; KIDNEY DISEASES; VITAMINS;

EID: 33846416976     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727020-00003     Document Type: Article

References (19)

1. Coresh J, Byrd-Holt D, Astor BC, et al. Chronic kidney disease awareness, prevalence, and trends among US adults, 1999 to 2000. J Am Soc Nephrol 2005 Jan; 16 (1): 180-8
2. US Renal Data System, USRDS 2004 Annual Data Report: atlas of end-stage renal disease in the United States. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2004
3. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003 Jan; 41 (1): 1-12
4. Smith DH, Gullion CM, Nichols G, et al. Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population. J Am Soc Nephrol 2004; 15 (5): 1300-6
5. Khan SS, Tighiouart H, Raman G, et al. Predicting cost among patients with chronic kidney disease. Poster Board Number SA-PO684. Presented at ASN 2003 Nov 15
6. Khan SS, Kazmi WH, Abichandani R, et al. Health care utilization among patients with chronic kidney disease. Kidney Int 2002 Jul; 62 (1): 229-36
7. Mix TC, St Peter WL, Ebben J, et al. Hospitalization during advancing chronic kidney disease. Am J Kidney Dis 2003 Nov; 42 (5): 972-81
8. Robbins JD, Kim JJ, Zdon G, et al. Resource use and patient care associated with chronic kidney disease in a managed care setting. J Manag Care Pharm 2003; 9 (3): 238-47
9. Wavamunno MD, Harris DC. The need for early nephrology referral. Kidney Int Suppl 2005 Apr; (94): S128-32
10. Owen Jr WF. Patterns of care for patients with chronic kidney disease in the United States: dying for improvement. J Am Soc Nephrol 2003 Jul; 14 (7 Suppl. 2): S76-80
11. Stack AG. Impact of timing of nephrology referral and pre-ESRD care on mortality risk among new ESRD patients in the United States. Am J Kidney Dis 2003 Feb; 41 (2): 310-08
12. Schmidt RJ, Dominico JR, Sorkin MI, et al. Early referral and its impact on emergent first dialyses, health care costs, and outcome. Am J Kidney Dis 1998; 32: 278-83
13. Levin A, Lewis M, Mortiboy P, et al. Multidisciplinary predialysis programs: quantification and limitations of their impact on patient outcomes in two Canadian settings. Am J Kidney Dis 1997; 29: 533-40
14. Astor BC, Eustace JA, Powe NR, et al. Timing of nephrologist referral and arteriovenous access use: the CHOICE study. Am J Kidney Dis 2001; 38: 494-501
15. Kim G, Sprague SM. Use of vitamin D analogs in chronic renal failure. Adv Ren Replace Ther 2002 Jul; 9 (3): 175-83
16. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003 Jul 31; 349 (5): 446-56
17. Sprague SM, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003 Apr; 63 (4): 1483-90
18. Dobrez DG, Mathes A, Amdahl M, et al. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant 2004 May; 19 (5): 1174-81
19. Diagnosis Related Groups (DRG) Handbook 2002. Evanston (IL): Solucient Publications